In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Eli Lilly just gave investors several reasons to cheer.

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster ...

Eli Lilly and Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...